(Source: Alnylam Pharmaceuticals Inc) 07.01.2016 - At 24 Months, Patisiran Shows a Mean 6.7 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7), Comparing Favorably with an Expected Mean 26-30 Point Increase Estimated from Historical Data - - In New Individual Patient Analysis, Over 70 Percent of Patisiran Patients Show Improvement or No Change in mNIS+7 at 24 Months, Supportive of Therapeutic Hypothesis that Patisiran can Potentially Halt or Improve Neuropathy Progression - - In APOLLO Phase 3 Study of Patisiran, Baseline Demographics Reveal Enrollment of a Globally Representative Patient Population with a Wide Range of Disease Severity and TTR Mutations, Including 54 Percent...
↧